Effect of Interleukin-6 Receptor Antagonists in Critically Ill Adult Patients with COVID-19 Pneumonia: two Randomised Controlled Trials of the CORIMUNO-19 Collaborative Group

CONCLUSION: In critically ill patients with COVID-19, anti-IL-6 Receptors did not significantly increase the number of patients alive without any NIV, MV by D14.TRIAL REGISTRATION: ClinicalTrials.gov numbers: (NCT04331808 and NCT04324073).PMID:35115337 | DOI:10.1183/13993003.02523-2021

Source: Respiratory Care - February 4, 2022 Category: Respiratory Medicine Authors: Olivier Hermine Xavier Mariette Raphael Porcher Matthieu Resche-Rigon Pierre-Louis Tharaux Philippe Ravaud on the behalf of the CORIMUNO-19 collaborative group Source Type: research